Please assess the completion status of the following clinical trial:

Trial Title: Placebo Effects in the Treatment of Depression: Cognitive and Neural Mechanisms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women aged 24-75 years~* Diagnosed with Diagnostic and Statistical Manual of Mental Disorders (DSM) IV Major Depressive Disorder, nonpsychotic~* 24-item Hamilton Rating Scale for Depression (HRSD) score ≥ 16~* Willing to and capable of providing informed consent and complying with study procedures~* Subjects are right-handed~* Using appropriate contraceptive method if woman of child-bearing age~Exclusion Criteria:~* Current comorbid Axis I DSM IV disorder other than Nicotine Dependence, Adjustment Disorder, Panic Disorder, Generalized Anxiety Disorder, or Social Phobia~* Diagnosis of substance abuse or dependence (excluding Nicotine Dependence) within the past 12 months~* History of psychosis or psychotic disorder, mania or bipolar disorder~* Subject is considered to be at significant risk of suicide based on current mental status and recent history~* History of allergic or adverse reaction to citalopram, or nonresponse to adequate trial of citalopram (at least 4 weeks at dose of 40mg) or escitalopram (at least 4 weeks at dose of 20mg)~* Subject is considered based on history to be unlikely to respond to the single agent citalopram (i.e., subjects with treatment resistant depression)~* Current treatment with psychotherapy~* Clinical Global Impression (CGI)-Severity score of 7 at baseline Clinical Interview~* Current or recent (within the past 4 weeks) treatment with any of the following: antidepressants, antipsychotics, mood stabilizers, isoniazid, glucocorticoids, opiates, centrally active antihypertensive drugs (e.g. clonidine, reserpine)~* Subject has metal in body or prior history working with metal fragments (e.g., as a machinist), tattoos, or unable to tolerate the scanning procedures (i.e., severe obesity, claustrophobia)~* Acute, severe, or unstable medical illness

- Gender: FEMALE
- Minimum Age: 24 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Open Track (Type: ACTIVE_COMPARATOR): Open treatment with 20mg of citalopram, increased to 40mg if depression has not remitted at week 4.
- Placebo Track (Type: PLACEBO_COMPARATOR): Blinded treatment with either citalopram 20mg or placebo, increased to citalopram 40mg or placebo at week 4 if depression has not remitted.

Based on this trial design, predict the completion outcome and termination type (if applicable).